Specialty drug distributor Diplomat Pharmacy files for a $100 million IPO

By
A A A

Diplomat Pharmacy, which operates the fourth largest specialty pharmacy in the US, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. The company distributes drugs that require coordinated regimens required by patients with complex chronic diseases.

It claims to be the largest independent specialty pharmacy in the US and competes with multinational pharmacies Express Scripts ( ESRX ), Walgreens ( WAG ) and CVS Caremark ( CVS ). The company is controlled by its founder and CEO, Philip Hagerman (73% pre-IPO stake), and other primary shareholders include EVP of Operations Jeffrey Rowe (7%), T. Rowe Price and the Janus Capital Group.

The Flint, MI-based company was founded in 1975 and booked $1.6 billion in sales for the 12 months ended March 31, 2014. Credit Suisse, Morgan Stanley, J.P. Morgan and Wells Fargo are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ESRX , WAG , CVS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

How to Fire Your Adviser
How to Fire Your Adviser            

Stocks

Referenced

50%
100%
100%

Most Active by Volume

75,750,465
  • $16.77 ▲ 0.36%
59,791,764
  • $101.58 ▲ 0.71%
38,720,622
  • $42.59 ▼ 0.28%
37,416,417
  • $46.52 ▼ 0.51%
35,101,793
  • $16.28 ▲ 0.74%
34,987,975
  • $99.53 ▲ 0.15%
33,760,830
  • $3.63 ▲ 0.69%
32,148,671
  • $17.61 ▲ 0.57%
As of 9/17/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com